An FDA safety review has determined the type 2 diabetes medicines Onglyza, Nesina, and Kombiglyze may increase the risk of heart failure, particularly in patients who already have heart or kidney disease. As a result, the FDA is adding new warnings to the drug labels about this safety issue.
Other diabetes drugs covered by this heart failure warning are:
If you take Onglyza, Nesina, Kombiglyze or one of the other drugs listed above, you should contact your health care professional right away if you develop signs and symptoms of heart failure such as:
- Unusual shortness of breath during daily activities
- Trouble breathing when lying down
- Tiredness, weakness, or fatigue
- Weight gain with swelling in the ankles, feet, legs, or stomach
You should not stop taking any medicine without first talking to a health care professional. Read the FDA MedWatch Drug Safety alert.
Onglyza (Saxagliptin) was approved in for the treatment of type 2 diabetes in 2009. Since its release in 2009, Onglyza (a joint effort between AstraZeneca and Bristol-Myers Squibb) has quickly become a strong selling drug, topping $700 Million in sales in the year 2011 and over $1 Billion in 2015.
If you or a loved one have taken Onglyza, Nesina or Kombiglyze and been diagnosed with heart failure/congestive heart failure, contact us online or call 1-866-252-3535 for a free consultation.